Shares in an leading ASX-listed biotech have lost nearly all of their value after its lead drug candidate failed as a lung cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results